2.50
Hdl Handle:
http://hdl.handle.net/10541/72697
Title:
MT-103 Micromet/MedImmune.
Authors:
Cheadle, Eleanor J
Abstract:
Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
Affiliation:
Paterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M204BX, UK. Echeadle@picr.man.ac.uk
Citation:
MT-103 Micromet/MedImmune. 2006, 8 (1):62-8 Curr. Opin. Mol. Ther.
Journal:
Current Opinion in Molecular Therapeutics
Issue Date:
Feb-2006
URI:
http://hdl.handle.net/10541/72697
PubMed ID:
16506527
Type:
Article
Language:
en
ISSN:
1464-8431
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorCheadle, Eleanor J-
dc.date.accessioned2009-07-07T09:48:05Z-
dc.date.available2009-07-07T09:48:05Z-
dc.date.issued2006-02-
dc.identifier.citationMT-103 Micromet/MedImmune. 2006, 8 (1):62-8 Curr. Opin. Mol. Ther.en
dc.identifier.issn1464-8431-
dc.identifier.pmid16506527-
dc.identifier.urihttp://hdl.handle.net/10541/72697-
dc.description.abstractMicromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.en
dc.language.isoenen
dc.subject.meshAnimals-
dc.subject.meshAntibodies, Bispecific-
dc.subject.meshClinical Trials, Phase I as Topic-
dc.subject.meshDrug Industry-
dc.subject.meshHumans-
dc.subject.meshLymphoma, B-Cell-
dc.subject.meshStructure-Activity Relationship-
dc.titleMT-103 Micromet/MedImmune.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M204BX, UK. Echeadle@picr.man.ac.uken
dc.identifier.journalCurrent Opinion in Molecular Therapeuticsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.